OverviewSuggest Edit

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company's primary focus is on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy drug candidates.

TypePublic
Founded1980
HQCambridge, MA, US
Websitesarepta.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Dec 2019)743(+49%)
Revenue (FY, 2019)$380.8 M(+27%)
Share Price (Jan 2021)$89.8 (+10%)
Cybersecurity ratingBMore

Key People/Management at Sarepta Therapeutics

Douglas S. Ingram

Douglas S. Ingram

President, Chief Executive Officer & Director
Diane Berry

Diane Berry

Senior Vice President, Global Health Policy and Government and Patient Affairs
Ian M. Estepan

Ian M. Estepan

Senior Vice President, Chief of Staff and Corporate Affairs
Gilmore O'Neill

Gilmore O'Neill

Executive Vice President, R&D and Chief Medical Officer
Louise Rodino-Klapac

Louise Rodino-Klapac

Executive Vice President, Chief Scientific Officer
Joan Nickerson

Joan Nickerson

Senior Vice President, Human Resources
Show more

Sarepta Therapeutics Office Locations

Sarepta Therapeutics has offices in Cambridge, Canton, Providence, Boulogne-Billancourt and in 7 other locations
Cambridge, MA, US (HQ)
215 First St
Canton, MA, US
250 Royall St
Boulogne-Billancourt, FR
90 Route de la Reine
Berlin, DE
Friedrichstraße 88
Dublin, IE
Regus House, Harcourt Centre, Saint Kevin's
Milano, IT
Piazzale Biancamano, 8
Show all (12)

Sarepta Therapeutics Financials and Metrics

Sarepta Therapeutics Revenue

Sarepta Therapeutics's revenue was reported to be $380.83 m in FY, 2019
USD

Revenue (Q3, 2020)

143.9m

Net income (Q3, 2020)

(196.5m)

EBIT (Q3, 2020)

(137.1m)

Market capitalization (11-Jan-2021)

7.1b

Closing stock price (11-Jan-2021)

89.8

Cash (30-Sept-2020)

1.5b

EV

6.4b
Sarepta Therapeutics's current market capitalization is $7.1 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

37.3m14.2m9.8m1.3m5.4m154.6m301.0m380.8m

Revenue growth, %

(31%)(87%)333%

Cost of goods sold

130.0k

Gross profit

5.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

4.5m3.0m4.2m6.1m2.6m1.1m16.3m35.0m46.0m64.6m73.5m78.5m87.0m94.7m99.0m113.7m137.4m143.9m

Cost of goods sold

252.0k534.0k

Gross profit

16.1m34.5m

Gross profit Margin, %

98%98%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

39.9m187.7m257.0m73.6m80.3m122.4m599.7m370.8m835.1m

Accounts Receivable

3.6m4.7m3.5m2.4m4.0m5.2m29.5m49.0m90.9m

Prepaid Expenses

1.6m1.5m3.1m35.0m17.4m36.5m77.8m81.9m

Inventories

12.8m83.6m125.4m171.4m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(2.3m)(121.3m)(112.0m)(135.8m)(220.0m)(267.3m)(50.7m)(361.9m)(715.1m)

Depreciation and Amortization

1.3m1.5m1.3m3.7m5.2m5.6m8.1m12.2m30.5m

Inventories

(12.8m)(70.8m)(41.8m)(45.9m)

Accounts Payable

9.5m10.8m
USDQ2, 2011

Financial Leverage

2.1 x
Show all financial metrics

Sarepta Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Sarepta Therapeutics Online and Social Media Presence

Embed Graph

Sarepta Therapeutics News and Updates

Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 11, 2021 at 1…

Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

-- Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants versus placebo -- -- SRP-9001-treated participants showed an increase in NSAA total score compared to placebo at 48 weeks; how…

Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

-- Results from the multiple-ascending dose trial demonstrate proof-of-concept for SRP-5051 and support continued dose escalation -- -- At a total dose exposure approximately 10x lower than eteplirsen, SRP-5051 at 20 mgs/kg showed enhanced tissue exposure, greater exon skipping, and greater dystroph…

Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy

CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Dec. 7, 2020 at 8:30 am Eastern Time (ET), it will host a webcast and conference call to present interim data fr…

Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020

-- Sarepta is honored to be recognized for offering a range of benefits and work-life resources to employees and supporting the local community -- -- Rankings based on confidential survey information submitted by employees to independent research company --
Show more

Sarepta Therapeutics Blogs

Sarepta Therapeutics at the 39th Annual JPMorgan Healthcare Conference Presentation and Q&A

Sarepta Therapeutics at the 39th Annual JPMorgan Healthcare Conference Presentation and Q&A Katherine.Howe… Thu, 12/31/2020 - 15:15 Sarepta Therapeutics at the 39th Annual JPMorgan Healthcare Conference Presentation and Q&A Display "add to calendar" true …

Sarepta Therapeutics Announces Executive Management Changes

Sarepta Therapeutics Announces Executive Management Changes Content Import Mon, 12/14/2020 - 08:30 Sarepta Therapeutics Announces Executive Management Changes 12/14/20 8:30 AM EST This release is a backfill from a News Wire Business & Financial …

Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Evercore ISI 3 rd Annual HealthCONx Virtual Conference on

Sarepta Therapeutics at the 29th Annual Credit Suisse Virtual Healthcare Conference

Sarepta Therapeutics at the 29th Annual Credit Suisse Virtual Healthcare Conference Katherine.Howe… Mon, 11/02/2020 - 16:51 Sarepta Therapeutics at the 29th Annual Credit Suisse Virtual Healthcare Conference Display "add to calendar" true Event Type …

Sarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the 29 th Annual Credit Suisse Virtual Healthcare Conference on

Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy Ephraim.DeGuia… Wed, 09/09/2020 - 17:19 Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment…
Show more

Sarepta Therapeutics Frequently Asked Questions

  • When was Sarepta Therapeutics founded?

    Sarepta Therapeutics was founded in 1980.

  • Who are Sarepta Therapeutics key executives?

    Sarepta Therapeutics's key executives are Douglas S. Ingram, Diane Berry and Ian M. Estepan.

  • How many employees does Sarepta Therapeutics have?

    Sarepta Therapeutics has 743 employees.

  • What is Sarepta Therapeutics revenue?

    Latest Sarepta Therapeutics annual revenue is $380.8 m.

  • What is Sarepta Therapeutics revenue per employee?

    Latest Sarepta Therapeutics revenue per employee is $512.6 k.

  • Who are Sarepta Therapeutics competitors?

    Competitors of Sarepta Therapeutics include Moderna, Intarcia Therapeutics and CureVac.

  • Where is Sarepta Therapeutics headquarters?

    Sarepta Therapeutics headquarters is located at 215 First St, Cambridge.

  • Where are Sarepta Therapeutics offices?

    Sarepta Therapeutics has offices in Cambridge, Canton, Providence, Boulogne-Billancourt and in 7 other locations.

  • How many offices does Sarepta Therapeutics have?

    Sarepta Therapeutics has 12 offices.